feedback

Course Director

Paul Cornes, BA, BM BCH, MA, MRCP, FRCR
Paul Cornes, BA, BM BCH, MA, MRCP, FRCR

Oncologist, Comparative Outcomes Group
Bristol, United Kingdom

Faculty

Christian Buske
Christian Buske, MD, PhD

Director, CCC Ulm
University Hospital Ulm
Ulm, Germany

Stephen Scowcroft
Stephen Scowcroft

Head of Business Development
Lymphoma Action
Aylesbury, United Kingdom

Arnold G. Vulto
Arnold G. Vulto, PharmD, PhD, FCP

Hospital Pharmacist, Erasmus University Medical Center
Rotterdam, The Netherlands
Professor, Clinical Pharmacology and Pharmacotherapy
KU Leuven Department of Pharmaceutical and Pharmacological Sciences
Leuven, Belgium

Accredited by

Oakstone Publishing, LLC

View Activity Materials

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2018-Jul-23
Expiration Date:2019-Jul-22
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of Charge

Funding Disclosure

This educational activity is supported by an unrestricted grant from Sandoz.

Activity Description and Educational Objectives

In this activity, experts discuss the role of biosimilars in addressing the economic burden of cancer care and improving patient access to therapy. The expert panel will examine the development process of biosimilars and the evidence supporting their use, as well as provide insights to facilitate the integration of these agents into the treatment of patients with haematologic malignancies.

Upon completion of this activity, participants should be better able to:
  • Describe the role of biosimilars in the long-term sustainability of treatments for haematologic malignancies
  • Evaluate the totality of evidence on biosimilar monoclonal antibodies for the treatment of haematologic malignancies, and explain why this concept is important
  • Outline key considerations when extrapolating data for use of biosimilars in clinical practice
  • Define potential strategies to optimise the use of biosimilars and expand access to care through the doctor/pharmacist relationship
  • Develop approaches to discuss the potential impact that biosimilars may have on the treatment of haematologic malignancies with patients

Target Audience

This activity has been designed to meet the educational needs of haematologists and haematologist-oncologists involved in the management of patients with haematologic malignancies.

Faculty Disclosure Statement / Conflict of Interest Policy

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director and Moderator

Paul Cornes, BA, BM BCH, MA, MRCP, FRCR
Oncologist, Comparative Outcomes Group
Bristol, United Kingdom

Paul Cornes, BA, BM BCH, MA, MRCP, FRCR, has a financial interest/relationship or affiliation in the form of:
Honoraria from Accord Healthcare; Amgen Inc.; Bernstein & Co.; F. Hoffmann-La Roche Ltd; Generic and Biosimilar Medicines Association (Australia); Hospira, Inc.; Janssen Pharmaceutical; Eli Lilly and Company; Merck Serono Ltd; Napp Pharmaceutical Group Ltd; PhAMA (Pharmaceutical Association of Malaysia); Pfizer Ltd; Sandoz Ltd; Synsana EEIG and Teva Pharmaceutical Industries Ltd.
Advisory Board for Accord Healthcare; Hospira, Inc.; and Pfizer Ltd.

Faculty

Christian Buske, MD, PhD
Director, CCC Ulm
University Hospital Ulm
Ulm, Germany

Christian Buske, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support form Bayer AG; F. Hoffmann-La Roche Ltd; and Janssen-Cilag Pharmaceuticals SA.
Speaker’s Bureau participant with AbbVie Inc.; F. Hoffmann-La Roche Ltd; Hexal AG; and Janssen-Cilag Pharmaceuticals SA.
Honoraria from AbbVie Inc.; F. Hoffmann-La Roche Ltd; Hexal AG; and Janssen-Cilag Pharmaceuticals SA.
Advisory Board for AbbVie Inc.; F. Hoffmann-La Roche Ltd; Hexal AG; and Janssen-Cilag Pharmaceuticals SA.

Stephen Scowcroft
Head of Business Development
Lymphoma Action
Aylesbury, United Kingdom

Stephen Scowcroft has no financial interests/relationships or affiliations in relation to this activity.

Arnold G. Vulto, PharmD, PhD, FCP
Hospital Pharmacist, Erasmus University Medical Center
Rotterdam, The Netherlands
Professor, Clinical Pharmacology and Pharmacotherapy
KU Leuven Department of Pharmaceutical and Pharmacological Sciences
Leuven, Belgium

Arnold G. Vulto, PharmD, PhD, FCP, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc.; Biogen Idec Ltd; Hospira, Inc.; Novartis Pharma GmbH; Pfizer Inc.; Samsung Bioepis Co., Ltd.; and Sandoz Ltd.
Speaker’s Bureau participant with Amgen Inc.; Biogen Idec Ltd; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; FeBelGen asbl; Hexal AG; Medicines for Europe AISBL; Mundipharma GmbH; and Sandoz Ltd.
Advisory Board for AbbVie Inc.; Amgen Inc.; Biogen Idec Ltd; Boehringer Ingelheim GmbH; Hexal AG; Hospira, Inc.; Pfizer Inc.; and Sandoz Ltd.

PeerVoice Medical Director

Sonia Schursky has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabelled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and PeerVoice. Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 70% is needed.

Media: Enduring Material
Release and Expiration Dates: July 23, 2018 - July 22, 2019
Time to Complete: 60 minutes

Disclaimer

Based on a panel discussion and on data from recent medical literature. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerCME or any of its supporters.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.



For technical assistance, please contact us.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.